Testosterone deficiency and chronic kidney disease.

Area of Science:

• Endocrinology
• Nephrology
• Men's Health

Background:

• Testosterone is crucial for reproductive and systemic health, impacting muscle, bone, cardiovascular, and cognitive functions.
• Testosterone deficiency (male hypogonadism) is linked to chronic kidney disease (CKD), affecting millions globally.
• Men with CKD often have low testosterone, worsening muscle wasting, quality of life, and cardiovascular risk, increasing morbidity and mortality.

Purpose of the Study:

• To explore the intricate relationship between testosterone levels and chronic kidney disease.
• To investigate the potential benefits and risks of testosterone replacement therapy (TRT) in patients with CKD.
• To emphasize the need for integrated care and careful monitoring in managing male hypogonadism in CKD.

Main Methods:

• Review of current research on testosterone's role in systemic health and its connection to CKD.
• Analysis of mechanisms linking CKD to testosterone deficiency, including the uremic environment and inflammation.
• Evaluation of potential therapeutic outcomes and adverse effects of TRT in CKD patients.

Main Results:

• CKD's uremic environment and associated factors disrupt the hypothalamic-pituitary-gonadal axis, leading to testosterone deficiency.
• TRT may improve muscle mass, anemia, bone density, and cardiovascular health in CKD patients.
• Potential risks of TRT in CKD include fluid retention, hypertension, and possible renal disease progression, necessitating careful patient selection.

Conclusions:

• The interplay between testosterone and CKD is complex, with deficiency impacting overall health and potentially worsening CKD.
• TRT shows promise for improving various health aspects in CKD patients but requires cautious application due to risks.
• Integrated, multidisciplinary care is essential for optimizing outcomes and quality of life for CKD patients with male hypogonadism.